REG - Smith & Nephew Plc - Change in Director Details

Smith & NephewAnnouncement

23/02/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240223:nRSW8090Da&default-theme=true

RNS Number : 8090D  Smith & Nephew Plc  23 February 2024

23 February 2024

 
 

SMITH & NEPHEW PLC

Notification under Listing Rule 9.6.14

 

 

Anne-Francoise Nesmes, Chief Financial Officer of Smith & Nephew plc, will
join the Board of Sanofi S.A. as an independent non-executive director with
effect from 30 April 2024, subject to Sanofi shareholder approval.

 

 

 

 Enquiries

 Investors

 Andrew Swift                      +44 (0) 1923 477433

 Katherine Rycroft                 +44 (0) 7811 270734

 Smith+Nephew

 Media

 Charles Reynolds                  +44 (0) 1923 477314

 Smith+Nephew

 Susan Gilchrist / Ayesha Bharmal  +44 (0) 20 7404 5959

Brunswick

 

About Smith+Nephew

 

Smith+Nephew is a portfolio medical technology business that exists to restore
people's bodies and their self-belief by using technology to take the limits
off living. We call this purpose 'Life Unlimited'. Our 19,000 employees
deliver this mission every day, making a difference to patients' lives
through the excellence of our product portfolio, and the invention and
application of new technologies across our three global business units of
Orthopaedics, Advanced Wound Management and Sports Medicine & ENT.

 

Founded in Hull, UK, in 1856, we now operate in more than 100 countries, and
generated annual sales of $5.2 billion in 2022. Smith+Nephew is a constituent
of the FTSE100 (LSE:SN, NYSE:SNN). The terms 'Group' and 'Smith+Nephew' are
used to refer to Smith & Nephew plc and its consolidated subsidiaries,
unless the context requires otherwise.

 

For more information about Smith+Nephew, please visit www.smith-nephew.com
(https://nam11.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.smith-nephew.com%2F&data=05%7C01%7CGuy.Impey%40smith-nephew.com%7C9e3982a8b2004f2d08ca08dba9320205%7C273106dc287842ebb7c8069dcf334687%7C0%7C0%7C638289806651381436%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=2hF%2FTSk63oh4YJW3eZfzkSgR3%2BFjWGe%2BxVlWQFzSfjY%3D&reserved=0)
and follow us on X
(https://nam11.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.twitter.com%2Fsmithnephewplc&data=05%7C01%7CGuy.Impey%40smith-nephew.com%7C9e3982a8b2004f2d08ca08dba9320205%7C273106dc287842ebb7c8069dcf334687%7C0%7C0%7C638289806651381436%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=lQVZ1OUugIOnCa1TKjRpZP2Y1Ky3tOb6DqLrdJZkcdM%3D&reserved=0)
, LinkedIn
(https://nam11.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fsmith-%2526-nephew&data=05%7C01%7CGuy.Impey%40smith-nephew.com%7C9e3982a8b2004f2d08ca08dba9320205%7C273106dc287842ebb7c8069dcf334687%7C0%7C0%7C638289806651381436%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=UjobX6fEdzz6DoYqA373OJv4asc9sLp0mK9z5%2FmLdkw%3D&reserved=0)
, Instagram
(https://nam11.safelinks.protection.outlook.com/?url=https%3A%2F%2Fwww.instagram.com%2Fsmithnephewmeded%2F&data=05%7C01%7CGuy.Impey%40smith-nephew.com%7C9e3982a8b2004f2d08ca08dba9320205%7C273106dc287842ebb7c8069dcf334687%7C0%7C0%7C638289806651381436%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=1FfF7EgKhIqMCstwPl28DCgBMDQGrr98RoSM4%2F9BPVk%3D&reserved=0)
or Facebook
(https://nam11.safelinks.protection.outlook.com/?url=http%3A%2F%2Fwww.facebook.com%2Fsmithnephewplc&data=05%7C01%7CGuy.Impey%40smith-nephew.com%7C9e3982a8b2004f2d08ca08dba9320205%7C273106dc287842ebb7c8069dcf334687%7C0%7C0%7C638289806651381436%7CUnknown%7CTWFpbGZsb3d8eyJWIjoiMC4wLjAwMDAiLCJQIjoiV2luMzIiLCJBTiI6Ik1haWwiLCJXVCI6Mn0%3D%7C3000%7C%7C%7C&sdata=QdZJhDpmPsCNSqnN5rkws3VrGwwxGes6p7NQPo1N7og%3D&reserved=0)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAZBLFLZLLLBBD